Tag: TNBC
Everest Medicines to Initiate a Registration Study in China for Sacituzumab...
China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...
Boehringer Ingelheim Venture Fund and PPF Group Close a US $...
Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...
Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...
Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...
Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...
Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...
Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...
Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...
Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple...
Seattle Genetics has signed a clinical collaboration agreement with Genentech, a member of the Roche Group, for the evaluation of its investigational antibody-drug conjugate...
Sacituzumab Govitecan Show Promising Results in Patients with Advanced Triple-negative Breast...
A clinical trial of an antibody-drug conjugate that combines the active portion of a chemotherapy drug with an antibody targeting a molecule expressed on...
SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...
Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...
New Patents Awarded for Immunomedics’ Antibody-drug Conjugates Development Program
Earlier this week Immunomedics announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent 9,492,566, the 32nd U.S. patent protecting the...
Studies Show Glembatumumab Vedotin to be Effective in a Wide Range...
During the annual meeting of the American Association for Cancer Research (AACR) being held  April 16 - 20, 2016 in New Orleans, LA, Celldex...
